Celltrion’s Remsima SC Ready For Early 2020 Launch
Formal EU Approval Received For ‘Biobetter’ Subcutaneous Infliximab
Executive Summary
Celltrion says it is ready to roll out its Remsima SC subcutaneous infliximab in Europe in the first quarter of 2020, after receiving a formal pan-European marketing authorization from the European Commission.
You may also be interested in...
Hikma Adds Remsima SC To Celltrion MENA Collaboration
Hikma has added Celltrion’s Remsima SC subcutaneous formulation of biosimilar infliximab to a marketing alliance in the MENA region that already includes three other Celltrion biosimilars.
Celltrion Healthcare Gears Up For Infliximab SC Launch
As Celltrion Healthcare prepares to roll out Remsima SC, its subcutaneous infliximab, in Europe – starting in the UK and Germany – Celltrion Healthcare’s UK commercial head, Matthew Eddleston, speaks to Generics Bulletin about how the innovative biosimilar will be positioned in the market.
Celltrion Sets Out Strategy For China
Celltrion has unveiled plans to construct a biologics plant in Wuhan, China, as well as setting up a direct sales network in the country, as part of its wider global strategy that also involves launching a new biosimilar every year to 2030.